Pharmaceutical drug developer Acrux could release the results of a phase III clinical trial of its menopause drug as early as Monday. Acrux shares were placed in a trading halt yesterday after the company revealed it had information that would probably have a material effect on the value of its securities -- but which it could not announce immediately. The Age (http://www.theage.com.au/news/business/acrux-shares-in-pause-over-menopause-drug-trial/2006/05/05/1146335926560.html)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Devicemakers Pay $9.5 Million for Selling Uncleared Products
The FDA hit Instrumed with a warning letter in 2014.
Federal Circuit Won’t Rehear Purdue Pharma’s OxyContin Patent Claims
The U.S. Court of Appeals for the Federal Circuit turned down Purdue’s appeal and upheld the PTAB ruling.
